FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Silver Andrew Jacob
(Last) (First) (Middle)
C/O CRISPR THERAPEUTICS
105 WEST FIRST STREET
(Street)
BOSTON MA 02127
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/19/2026 		3. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (1) 11/01/2028 Common Shares 4,892 35.59 D  
Stock Option (Right to Buy)   (2) 10/22/2029 Common Shares 1,395 39 D  
Stock Option (Right to Buy)   (3) 03/10/2030 Common Shares 2,805 44.67 D  
Stock Option (Right to Buy)   (4) 10/05/2030 Common Shares 1,800 86.75 D  
Stock Option (Right to Buy)   (5) 03/11/2031 Common Shares 4,522 133.88 D  
Stock Option (Right to Buy)   (6) 10/15/2031 Common Shares 1,966 97 D  
Stock Option (Right to Buy)   (7) 02/18/2032 Common Shares 3,840 58.29 D  
Stock Option (Right to Buy)   (8) 10/07/2032 Common Shares 2,366 61.65 D  
Stock Option (Right to Buy)   (9) 03/10/2033 Common Shares 8,431 43.22 D  
Stock Option (Right to Buy)   (10) 10/13/2033 Common Shares 3,766 44.31 D  
Stock Option (Right to Buy)   (11) 03/20/2034 Common Shares 9,039 72.94 D  
Stock Option ( Right to Buy)   (12) 10/16/2034 Common Shares 3,766 49 D  
Stock Option (Right to Buy)   (13) 03/14/2035 Common Shares 18,734 42.12 D  
Stock Option (Right to Buy)   (14) 10/03/2035 Common Shares 6,944 67.74 D  
Stock Option (Right to Buy)   (15) 03/20/2036 Common Shares 14,874 46.24 D  
Restricted Stock Units   (16)   (16) Common Shares 1,300 (17) D  
Restricted Stock Units   (18)   (18) Common Shares 3,390 (17) D  
Restricted Stock Units   (19)   (19) Common Shares 15,000 (17) D  
Restricted Stock Units   (20)   (20) Common Shares 8,437 (17) D  
Restricted Stock Units   (21)   (21) Common Shares 12,000 (17) D  
Restricted Stock Units   (22)   (22) Common Shares 15,000 (17) D  
Restricted Stock Units   (23)   (23) Common Shares 10,000 (17) D  
Explanation of Responses:
1. This option was granted on November 1, 2018 with respect to 10,000 Common Shares. 25% of the shares vested on November 1, 2019, with the remaining shares vested in 48 equal monthly installments thereafter.
2. This option was granted on October 22, 2019 with respect to 1,716 Common Shares. 100% of the shares vested in 48 equal monthly installments, with the first installment vested on November 22, 2019.
3. This option was granted on March 10, 2020 with respect to 3,960 Common Shares. 100% of the shares vested in 48 equal monthly installments, with the first installment vested on April 10, 2020.
4. This option was granted on October 5, 2020 with respect to 1,800 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 5, 2020.
5. This option was granted on March 11, 2021 with respect to 4,522 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on April 11, 2021.
6. This option was granted on October 15, 2021 with respect to 1,966 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 15, 2021.
7. This option was granted on February 18, 2022 with respect to 3,840 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on March 18, 2022.
8. This option was granted on October 7, 2022 with respect to 2,366 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 7, 2022.
9. This option was granted on March 10, 2023 with respect to 8,431 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on April 10, 2023.
10. This option was granted on October 13, 2023 with respect to 3,766 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 13, 2023.
11. This option was granted on March 20, 2024 with respect to 9,039 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on April 20, 2024.
12. This option was granted on October 16, 2024 with respect to 3,766 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 16, 2024.
13. This option was granted on March 14, 2025 with respect to 18,734 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on April 14, 2025.
14. This option was granted on October 3, 2025 with respect to 6,944 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 3, 2025.
15. This option was granted on March 20, 2026 with respect to 14,874 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on April 20, 2026.
16. This restricted stock unit award was granted on March 10, 2023 with respect to 5,202 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.
17. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
18. This restricted stock unit award was granted on March 20, 2024 with respect to 6,780 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.
19. This restricted stock unit award was granted on December 18, 2024 with respect to 15,000 Common Shares, with 100% of the shares vesting on December 18, 2027.
20. This restricted stock unit award was granted on March 14, 2025 with respect to 11,250 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.
21. This restricted stock unit award was granted on December 16, 2025 with respect to 12,000 Common Shares, with 100% of the shares vesting on December 16, 2028.
22. This restricted stock unit award was granted on March 20, 2026 with respect to 15,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027, (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030.
23. This restricted stock unit award was granted on May 29, 2026 with respect to 10,000 Common Shares, with 100% of the shares vesting on November 29, 2028.
/s/ Andrew Jacob Silver 10/21/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EX-24